MA-NUMARES
21.1.2021 12:02:09 CET | Business Wire | Press release
Leading metabolomics based diagnostics company numares AG and analytical instrumentation and solution provider Bruker Corporation have signed an agreement to collaborate to bring new diagnostics tests utilizing NMR to the laboratory market for unmet medical needs. The tests are based on the automated measurement of metabolites using a strong magnet field, and artificial intelligence. The platform is marketed under the numares brand AXINON® .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005438/en/
Based on a longstanding collaboration between the two companies, the agreement creates a combination of numares ’ expertise in leveraging metabolomics for software-based diagnostics with world-leading nuclear magnetic resonance (NMR) technology from Bruker. This leads to more rapid, accurate and personalized information about the severity and progress of diseases.
This collaboration will support the ongoing transition of AXINON® platform from research into routine clinical use, and makes it available to all patients as an affordable, day-to-day diagnostic standard. Two years ago, numares started a collaboration with US-based Mayo Clinic for joint diagnostic test development using metabolomics and NMR. The collaboration of numares and Bruker now marks a further milestone in the numares vision to bring these technologies into routine diagnostics.
The AXINON® platform based on NMR spectroscopy is a non-invasive technique that is uncovering new potential for the prevention and treatment of disease, including conditions in the kidney, heart, and liver, as well as cancer. The numares system measures various metabolic patterns and applies artificial intelligence (AI) to cluster and translate the results into clinical diagnosis. This rich source of information gives healthcare professionals new insight into disease management, and gives patients fast access to the right treatment. Likewise, the AXINON® platform also supports disease risk prediction, paving the way to new developments in precision medicine and companion diagnostics.
Dr. Volker Pfahlert, Director of the Board of numares says: “Our agreement will help to expand the exciting potential of NMR technology, long established in academic and clinical research, to the clinical diagnostics industry where numares already has a strong customer base. It paves the way for market entry of NMR diagnostics under FDA regulations, a prerequisite to make it accessible to all patients as day-to-day applications in routine clinical diagnostics. It will support numares to better utilize its test development in several indications such as kidney disease, liver disease or neurological disorders.”
Dr. Iris Mangelschots, President of Bruker BioSpin’s Applied, Clinical and Industrial division comments: “The pandemic of 2020 has brought unimaginable challenges on a global scale. With the world’s spotlight sharply focused on the healthcare industry, our business has accelerated to develop the technology and diagnostic solutions that is desperately needed. The innovations born out of this demand have paved the way for future, highly advanced new product developments. Partnering with numares will bring our technology to the frontline healthcare industry, where it is most needed. NMR technology delivers the robust and reproducible results needed to support the advanced AI modelling techniques deployed by numares . Together, our complementary technologies offer a powerful arm in the fight against disease of the future.”
Co-CEO and President of numares Group Corp. Winton Gibbons concludes: “This agreement is a further important step in the commercialization of our products in the US. With GFRNMR we will soon launch a novel blood test to help identify and quantify impaired kidney function in patients with this more accurate, easy-to-access, and affordable diagnostic standard.”
About numares
numares AG, based in Regensburg, Germany, is a fast-growing innovative diagnostics company that applies machine learning to metabolomics data to develop advanced analytical tests for high-throughput use in clinical diagnostics. The AXINON® System employs advanced nuclear magnetic resonance (NMR) spectroscopy to evaluate metabolic constellations. Magnetic Group Signaling (MGS® ) is a proprietary technology that enables NMR for highly standardized and rapid throughput testing. Metabolic tests stand as an important pillar in precision medicine to address unmet needs in cardiovascular, kidney, liver, and neurological diseases. You will find more information at https://www.numares.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210121005438/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Premier Jumping League (PJL) & McCarthy Jumping Team Announce Landmark Purchase29.6.2026 15:10:00 CEST | Press release
With $50 Million Team Acquisition, McCarthy Jumping Team Becomes First PJL Ownership Group Acquisition illustrates strong investor confidence in the future of professional showjumping as highly anticipated 2027 inaugural season to feature 16 teams competing across 14 international events The Premier Jumping League (PJL) today announced that seasoned trader, investor, and competitive race car driver Jason McCarthy and McCarthy Jumping League LLC acquired the first PJL team in a landmark $50 million acquisition, building on rising momentum for the highly acclaimed professional jumping league. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629512997/en/ The Premier Jumping League (PJL), photographed by Daniel Benson. The milestone investment represents an unprecedented valuation for a team in a newly established sports competition and underscores the confidence that sophisticated investors are placing in the PJL. The inaugur
InvestEco Sustainable Food Fund IV Holds a Final Close With Total Commitments of C$106M29.6.2026 15:00:00 CEST | Press release
InvestEco Capital is pleased to announce the final close of the InvestEco Sustainable Food Fund IV. This fund will continue InvestEco’s work of investing in high-growth food companies that promote health and sustainability in the food sector. The Fund closed with total commitments of C$106M, the largest InvestEco fund to date. Investors include Farm Credit Canada, Export Development Canada, Business Development Bank of Canada, Fonds de solidarité FTQ, and two Government of Canada Social Finance Fund wholesalers: Boann and Realize Capital Partners. In addition, the Fund received commitments from a number of private investors and family offices. The Fund's investments to date include Humble Snacks, Little Sesame, Mid-Day Squares and Algae Cooking Club. The Fund expects to make a further 6 - 10 investments over the next few years. InvestEco Capital, founded in 2002, is a Toronto-based venture capital firm and impact investor focused on the sustainable food sector. For more information, em
Geoswift and SKUx Announce Strategic Partnership to Develop a First-of-Its-Kind Programmable Stablecoin Commerce Network29.6.2026 14:00:00 CEST | Press release
Bridging digital assets, traditional finance, enterprise treasury, and agentic commerce through global programmable money infrastructure Geoswift and SKUx announced a groundbreaking partnership to develop a next-generation programmable stablecoin commerce network. This strategic collaboration bridges digital assets, traditional finance, and real-world commerce at a global scale, representing a "one-of-one" opportunity by combining Geoswift's global infrastructure with SKUx's specialized item-level controls directly within point-of-sale (POS) systems. While enterprise stablecoin usage continues to accelerate globally, governments, enterprises, payment networks, and AI-driven commerce platforms are increasingly seeking programmable payment infrastructure that can bridge digital assets with real-world commerce. The innovation goes far beyond treasury management or even enabling consumers to spend stablecoins at retail locations. Instead, it unlocks true "programmable money" with embedded
Esri Sponsors Smithsonian Exhibition Showcasing Natural and Cultural Objects from All 50 States29.6.2026 14:00:00 CEST | Press release
From These Lands Exhibition Highlights Connections Between People, Place, and Natural World Through Physical Specimens and Digital Maps Esri is the lead sponsor of the Smithsonian's From These Lands exhibition and developed maps powered by ArcGIS and a digital companion to extend engagement beyond the museum. The exhibition features more than 600 specimens and cultural artifacts from all 50 states, Washington, DC, and US territories, drawn from the Smithsonian's National Museum of Natural History's collection of over 148 million objects. Designed around themes of connection, diversity, and discovery, the exhibit explores how landscapes, ecosystems, and cultural traditions shape one another across regions and time. Animated mapping experiences enable visitors to explore topography, biomes, geology, migration patterns, and watersheds, revealing relationships across the continent. ArcGIS StoryMaps transforms the physical exhibit into an accessible digital narrative, extending its reach to
Cartilage Tissue Engineering Heads to Orbit in NSF and NASA-supported Study at the International Space Station29.6.2026 14:00:00 CEST | Press release
UC Irvine researchers use single cell RNA sequencing to study cartilage tissue engineered in microgravity Researchers in the DELTAi Lab at the University of California, Irvine, working with NASA, are using Evercode Cell Fixation to preserve samples aboard the International Space Station as part of a study of cartilage tissue engineering in microgravity. The unprecedented work, part of a National Science Foundation (NSF)-funded grant led by Dr. Wendy Brown and Dr. Kyriacos Athanasiou, announced today by Parse Biosciences, aims to advance treatments for the hundreds of millions of people worldwide affected by cartilage injury. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629548658/en/ Rachel Nordberg, PhD, from the DELTAi Lab at UC Irvine, prepping the BioServe device before it goes into orbit. Cartilage injuries cause significant pain and disability, and the need for implants that can repair or regenerate damaged tissue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom